Filing Flows › Health Care › Invivyd (IVVD)
Invivyd (IVVD) earnings and revenue breakdown
Latest: Q2 2026 · 10-Q filed Aug 13, 2026 · Invivyd (IVVD) Q2 2026 earnings results →
Q2 2026 Revenue up 21% year over year to $14.3M · 311¢ of every $1 of revenue lost · operating margin -320.8%
Invivyd made $14.3M in Q2 2026 (+21% Y/Y). Operating margin -320.8%, net loss $44.4M. See where every dollar goes — costs, profit and cash — as a Sankey from the 10-Q filed Aug 13, 2026.
Drawing the Sankey…
Open the interactive Sankey → click any line for what the company wrote about it, compare Y/Y and Q/Q, export as PNG or PDF
What changed this quarter
Revenue was $14.3M in Q2 2026, up 21% year over year and up 4% from the previous quarter.
Operating costs exceeded revenue by $45.8M, an operating margin of -320.8%. Total costs grew 124% against revenue growth of 21%. The fastest-growing cost line was Research & development (+207%). The quarter ended with a net loss of $44.4M, wider than the previous quarter's $41.4M loss.
Operating cash flow was −$43.0M. Non-cash charges added back $2.9M of share-based compensation. Capital expenditures of $510K exceeded it, leaving free cash flow of −$43.5M.
Quarterly history
| Quarter | Form | Filed | Revenue | Y/Y | Op. margin | Net earnings | Op. cash flow |
|---|---|---|---|---|---|---|---|
| Q2 2026 | 10-Q | Aug 13, 2026 | $14.3M | +21% | -320.8% | −$44.4M | −$43.0M |
| Q1 2026 | 10-Q | May 14, 2026 | $13.7M | +22% | -313.9% | −$41.4M | −$41.7M |
| Q4 2025 | 10-K | Mar 5, 2026 | $17.2M | +24% | -73.0% | −$11.1M | −$15.5M |
| Q3 2025 | 10-Q | Nov 6, 2025 | $13.1M | +41% | -84.0% | −$10.5M | −$8.2M |
| Q2 2025 | 10-Q | Aug 14, 2025 | $11.8M | +421% | -127.8% | −$14.7M | −$13.3M |
| Q1 2025 | 10-Q | May 15, 2025 | $11.3M | — | -149.7% | −$16.3M | −$21.1M |
| Q4 2024 | 10-K | Mar 20, 2025 | $13.8M | — | -139.1% | −$18.4M | −$37.6M |
Charts
Interactive views
The same charts as the app — open one to draw it.
💵Where each $1 goesinteractive
Loading the interactive chart…
🌏Named in Asian annual reportsinteractive
Loading the interactive chart…
🔄Rotation against the market and its industry (RRG)interactive
Loading the interactive chart…
🔍Earnings qualityinteractive
Loading the interactive chart…
⚖️Fair value by methodinteractive
Loading the interactive chart…
🔭Outlook & guidanceinteractive
Loading the interactive chart…
📈Investments: gains and what it boughtinteractive
Loading the interactive chart…
🏭Its industry’s money flow (input-output)interactive
Loading the interactive chart…
About Invivyd
Invivyd, Inc. is a biopharmaceutical company focused on the discovery, development and commercialization of monoclonal antibody (“mAb”) therapies for the prevention and treatment of serious viral infectious diseases. We are devoted to delivering protection from serious viral infectious diseases, beginning with SARS-CoV-2, the virus that causes COVID-19. PEMGARDA® (pemivibart) is our first mAb to receive regulatory authorization and was designed to exert continuous pharmaceutical activity in the face of viral evolution. Globally, COVID-19 has caused millions of deaths and lasting health problems in many survivors and remains a significant global health concern, particularly for immunocompromised individuals.
In its own words, from its 10-K, filed Mar 5, 2026.
Invivyd against its Biological Products, (No Diagnostic Substances) peers
The largest companies of the same SEC industry, each at its latest quarter. Revenue growth: +21% against the peers' median +21%. Operating margin: -320.8% against the peers' median 35.8%.
| Company | Quarter | Revenue | Y/Y | Op. margin |
|---|---|---|---|---|
| IVVD Invivyd | Q2 2026 | $14.3M | +21% | -320.8% |
| AMGN Amgen | Q3 2026 | $10.4B | +8% | 35.8% |
| GILD Gilead Sciences | Q3 2026 | $8.3B | +7% | 41.7% |
| BIIB Biogen | Q3 2026 | $2.8B | +11% | -0.3% |
| MRNA Moderna | Q3 2026 | $1.3B | +29% | 9.9% |
| NBIX Neurocrine Biosciences | Q3 2026 | $1.1B | +41% | 29.5% |
| EXEL Exelixis | Q3 2026 | $659M | +10% | 40.8% |
| HALO Halozyme Therapeutics | Q3 2026 | $493M | +39% | 59.8% |
| MGTX MeiraGTx Holdings | Q2 2026 | $321M | 87× | 76.0% |
Source: Invivyd 10-Q on SEC EDGAR · CIK 1832038 · Biological Products, (No Diagnostic Substances)
13F: who owns IVVD and who is buying
More on IVVD
History
Every quarter: Q2 2026 results · Q1 2026 results · Q4 2025 results · Q3 2025 results · Q2 2025 results · Q1 2025 results · Q4 2024 results